Skip to main content
main-content

EULAR 2021 Virtual Congress coverage

2 – 5 June 2021
News highlight

​​​​​​​Rituximab, JAK inhibitors linked to worse COVID-19 severity in RA patients

Video highlight

COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity

Expert video interviews from the EULAR 2021 Virtual Congress

05-06-2021 | EULAR 2021 | Conference coverage | Video

First COVAX Registry data on COVID-19 vaccine safety for patients with RMDs

Pedro Machado presents COVID-19 vaccine safety data supporting their use for patients with rheumatic and musculoskeletal diseases.

04-06-2021 | EULAR 2021 | Conference coverage | Video

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial

Andrew Östör talks about the results of KEEPsAKE 2, a phase 3 trial of risankizumab versus placebo in patients with psoriatic arthritis, and explores how the IL-23 inhibitor may impact clinical practice if approved by the regulatory authorities.

04-06-2021 | EULAR 2021 | Conference coverage | Video

RESOLVE-1 fails to meet primary endpoint for lenabasum in patients with dcSSc

Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome.

IN FOCUS | Clinical trial updates on IL-23 inhibitors for PsA

News from the EULAR 2021 Virtual Congress

View more news from EULAR 2021 Virtual Congress


Medicine Matters conference coverage is brought to you in partnership with medwireNews